Radiolabeling of fab and f(ab 0 ) 2 were tested for stability by the cysteine challenge test. The immunoreactivity and binding affinity of the radiolabeled fragments were studied using in-vitro cell-binding assays. Radiochemical yields achieved for [ 99m Tc(CO) 3 ] + core labeling of fab and f(ab 0 ) 2 were 91.6 ± 9.1% and 80.7 ± 8.5%, respectively. Stability studies of radiolabeled antibody fragments showed that the 99m Tc label was stable to transchelation by cysteine. Both 99m Tc-fab and 99m Tc-f(ab 0 ) 2 retained their reactivity and affinity to the mesothelin antigen. From our studies, it can be concluded that the newly synthesized N-(ortho-phenol)-histidine chelator is a promising candidate for [ 99m Tc(CO) 3 ] + labeling of biomolecules and for developing other novel 99m Tc radiopharmaceuticals. Nucl Med Commun
Introduction
Development of biologically targeted radiotracers for scintigraphic imaging is a proven strategy for early detection and management of cancer, as most cancers with bad prognosis are best treated when diagnosed as early as possible. 99m Tc with a physical half-life of 6 h is widely recognized as the radionuclide of choice for developing novel targeted radiopharmaceuticals, for preventing excessive radiation dose to the patient, and for allowing optimal imaging due to its g energy of 140 keV [1, 2] .
Monoclonal antibodies (mAbs) or their fragments that recognize tumor-associated antigens can be applied as delivery vehicles for targeting radionuclides specifically to tumor sites [3] [4] [5] . The ability to successfully incorporate 99m Tc into targeting molecules is the foremost consideration in developing 99m Tc-based diagnostic radiopharmaceuticals. 99m Tc labeling of antibodies and their fragments has been a subject of considerable research and both direct and indirect labeling methods have been explored by researchers in the past [6] [7] [8] . Direct methods rely on covalently linking 99m Tc with the endogenous thiols of the antibody produced after reduction of its interchain and intrachain disulfide bridges. Indirect methods work by incorporating a bifunctional chelator between the biomolecule and 99m Tc, which acts as a strong chemical tether to hold 99m Tc within the radiopharmaceutical complex. Alberto et al. [9] described an indirect method for 99m Tc labeling using the 99m Tc [10, 11] , peptides [12, 13] , recombinant proteins [14] , and nucleotides [15] . Until now, the labeling of targeted biomolecules such as single chain variable fragment [16] , nanobodies [17] , minibodies [18] , and affibodies [19] 99m Tc-labeled diagnostic imaging probes we used fab and f(ab 0 ) 2 fragments of antibody mAbK1, which targets mesothelin antigen overexpressed in mesotheliomas, ovarian cancer, pancreatic cancer, and some other malignancies [20] [21] [22] . We further evaluated these radiolabeled antibody fragments for stability, immunoreactivity, and binding affinity.
Materials and methods
All chemicals and reagents were purchased from SigmaAldrich (Oakville, Ontario, Canada . Ultracel-YM30 and YM100 centrifugal filters were purchased from Millipore Corporation (Billerica, Massachusetts, USA). The radioactive thin layer chromatograms were autoradiographed using a phosphor imager (cyclone storage phosphor imager with a 20 Â 25 cm 2 phosphor screen; Perkin-Elmer, Waltham, Massachusetts, USA) and analyzed using OptiQuant software. Activity measurements were made using a Packard Cobra II Gamma Counter (Perkin-Elmer).
Methods

Synthesis of N-(ortho-phenol)-histidine chelator
N-(ortho-phenol)-histidine chelator was synthesized by adding salicylaldehyde (0.79 g, 6.5 mmol) in 15 ml of ethanol to a solution of L-histidine (1 g, 6.5 mmol) in 15 ml of H 2 O and stirring for 3 h at room temperature. NaBH(OAc) 3 (2.5 g) was added in small portions and the mixture was stirred overnight at room temperature. The white solid was filtered off, washed with ethanol, and dried under vacuum (Fig. 1 The antibody fragments of mAbK1 were prepared using the mouse IgG1 fab and f(ab 0 ) 2 preparation kit that uses immobilized Ficin (Pierce Biotechnology, Illinois, USA). Ficin generates fab fragments in the presence of 10 mmol/l cysteine when incubated for 5 h, and f(ab 0 ) 2 fragments in the presence of 1 mmol/l cysteine when incubated for 15-20 h. Different fractions containing fab or f(ab 0 ) 2 were collected, pooled, and concentrated using centrifugal filters with 30 and 100 kDa cut-off to yield the fab and f(ab 0 ) 2 fractions, respectively. Bradford's assay (Sigma) was carried out to determine the protein concentrations of the fab and f(ab 0 ) 2 fractions and a nonreducing western blot (data not shown) analysis was carried out to confirm the molecular weight of fragments. Radiolabeling of fab and f(ab 0 ) 2 was performed using the bifunctional chelate approach. The carboxylate group of N-(ortho-phenol)-histidine chelator was reacted with the free amines of the antibody fragments by carbodiimide coupling. A 25 ml solution of freshly prepared 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide [3 mg 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 6 mg N-hydroxysuccinimide in 0.5 ml of 2-(N-morpholino) ethanesulfonic acid (MES) buffer pH 4.5] was added to 50 ml of N-(ortho-phenol)-histidine chelator solution (6 mg in 1 ml MES buffer, pH 8.0). From this solution, 22.5 ml was added to 10 mg of antibody solution [fab or f(ab 0 ) 2 ] in 10 ml MES buffer (pH 4.5). The reaction mixture was adjusted to pH 7.0 and Tc-f(ab 0 ) 2 were incubated with 1 mmol/l cysteine solution (20 000-fold molar excess) at 371C and aliquots were taken at 1 and 24 h. Radiochemical yield measurements were taken to determine the stability of 99m Tc-labeled fragments to transchelation by cysteine. Control measurements of the respective samples were recorded by incubation with 0.9% saline. The percentage of 99m Tc displaced by cysteine was determined by ITLC using 0.9% saline as the mobile phase.
Cell culture NCI-H226 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 371C in a humidified atmosphere in the presence of 5% CO 2 .
Determination of immunoreactivity
The immunoreactivity of fab and f(ab 0 ) 2 fragments labeled with 99m Tc was determined by a cell-binding assay described by Lindmo et al. [23] . Varying concentrations (1 Â 10 6 to 5 Â 10 6 cells/ml) of mesothelin-expressing NCI-H226 cells were incubated with 100 ng of 99m Tc-fab or 99m Tc-f(ab 0 ) 2 fragments on a rocker at 41C for 2 h. After centrifugation, the supernatant was removed and cells were washed with the binding buffer (PBS with 1% BSA) and counted in a g-counter. This represents the total binding of 99m Tc-fab or 99m Tc-f(ab 0 ) 2 to NCI-H226 cells. To determine nonspecific binding, a second set of experiments was conducted exactly as described above, except that an excess of unlabeled mAbK1 (10 mg) was added to the Eppendorf tubes (Hamburg) containing different concentrations of cells before the addition of 99m Tc-fab or 99m Tc-f(ab 0 ) 2 . The difference between total and nonspecific binding is the specific NCI-H226 cell binding [21] . The immunoreactivities were calculated from the Y-intercept of the double-reciprocal plot of fraction of the radioactivity specifically bound versus the cell number.
Saturation binding assay -K d determination
Determination of the dissociation constant, K d , for 99m Tcfab and 99m Tc-f(ab 0 ) 2 , and maximum number of binding sites (B max ) for NCI-H226 was carried out using saturation cell-binding experiments [24] . In brief, approximately 50 000 NCI-H226 cells/well were plated overnight in a 24-well plate. Adherent cells were then incubated in serum-free culture media with increasing concentrations (0-80 nmol/l) of 99m Tc-fab and 99m Tcf(ab 0 ) 2 in a total volume of 500 ml for 3 h at 41C. The cells were then washed twice with ice-cold PBS to remove unbound radioactivity, dissolved in 0.1 mol/l NaOH, and analyzed in a g-counter. Prism version 5.0 software (GraphPad Software, San Diego, California, USA) was used to fit the total binding values against the concentration of unbound radiolabeled antibodies to a onesite saturation binding model. K d was determined using this model by fitting only total binding, assuming that the amount of nonspecific binding was proportional to the concentration of radioligand.
Results and discussion
In this study, we designed and synthesized the N-(orthophenol)-histidine chelator to bind the [ 99m Tc(CO) 3 ] + core to antimesothelin antibody fragments. For synthesis of the bifunctional chelator, we chose the single amino acid L-histidine, a natural amino acid, and modified it to the ligand as shown in Fig. 1 3 ] + produces a neutral metal complex, similar to another recently reported imidazolecontaining complex [25] . The carboxyl functional group of N-(ortho-phenol)-histidine chelator binds to the biological molecule whereas the rest of the molecules [imidazole (N), amine (N), and phenolate (O)] bind 99m Tc. Bioconjugation was based on the carbodiimide activation of the carboxylate of N-(ortho-phenol)-histidine chelator and further reaction with the amine groups present on the antibody fragments. Antibody fragments bear both e amines (lysine residues) and a amines (Nterminus). The e amines are good nucleophiles at a pH of more than 8.0, whereas a amine groups react well at neutral pHs [26] . Therefore, by maintaining the pH of the reaction mixture at 7.0, labeling of N-terminal a amine groups of the antibody fragments is favored. For 99m Tc labeling, [ 99m Tc(CO) 3 (H 2 O) 3 ] + was prepared using the Isolink kit from Covidien, which reliably produces the aqua-complex precursor with a radiochemical purity of greater than 98% [12, [27] [28] [29] . Radiolabeling of the N-(ortho-phenol)-histidine chelator-containing fragments was then performed by replacing the three aqua ligands of the complex precursor [ 99m Tc(CO) 3 
(H 2 O) 3 ]
+ with the tridentate chelator. Using this method, radiochemical yields of 91.6 ± 9.1% and 80.7 ± 8.5% were achieved for fab and f(ab 0 ) 2 , respectively (Fig. 2) . Rapid purification with centrifugal filters resulted in a radiochemical purity of greater than 95% for these fragments. However, the need for a final purification step is a considerable drawback for the clinical use of radiopharmaceuticals. Therefore, it is desirable to obtain higher radiochemical yields (> 95%), thus eliminating the need for purification.
Earlier, Chen et al. [30] reported direct 99m Tc labeling of the inherent histidine groups on the antibody herceptin (trastuzumab) by simply incubating the antibody with [ 99m Tc(CO) 3 + takes place in a nonspecific manner.
The bifunctional chelator N-(ortho-phenol)-histidine chelator holds 99m Tc securely attached to the radiopharmaceutical, while also providing a side arm for attachment of the antibody fragment. + core used hexahistidine end groups on affibodies for targeting the human epidermal growth factor receptor 2 antigen [19] , and nanobodies for targeting the epidermal growth factor receptor [17] . Labeling efficiencies and stabilities from these reports were similar to those observed in our study. For example, Orlova et al. [19] reported a 1-h cysteine challenge result 
Representative autoradiographic images of instant thin layer chromatography strips used for the determination of radiolabeling yield for 99m Tc-labeled (a) fab and (b) f(ab 0 ) 2 fragments. (c) Radiolabeling yield for 99m Tc-labeled fab fragment without using the chelator. The activity at R f = 0 corresponds to 99m Tc-fab in (a) and (c) or 99m Tc-f(ab 0 ) 2 in (b). R f = 1 corresponds to unbound 99m Tc. of 84% when a 5000-fold molar excess of cysteine was used, whereas our result was 79% with a 20 000-fold molar excess (Fig. 3 ). In the cysteine challenge studies, for the fab fragment, 79.5 ± 1.7% of radioactivity was antibodybound after 1 h, which decreased to 66.7 ± 4.9% after 24 h. For f(ab 0 ) 2 , 72.5 ± 2.8% of radioactivity was antibody-bound after 1 h, which decreased to 63.4 ± 0.5% after 24 h. Control studies carried out in 0.9% saline for 1 and 24 h at 371C indicated that the antibody and fragments retained greater than 90% of the radiolabel over 24 h. These results suggest that [ 99m Tc(CO) 3 ] + labeling using hexahistidine end groups is comparable with the bifunctional chelator N-(ortho-phenol)-histidine chelator-mediated labeling strategy used in our studies.
The immunoreactivity of 99m Tc-fab and 99m Tc-f(ab 0 ) 2 determined from the cell-binding assays was 82% and 80%, respectively. Both 99m Tc-fab and 99m Tc-f(ab 0 ) 2 retained their reactivity to the mesothelin antigen, suggesting that the bioconjugation of N-terminus amines did not cause any significant functional modification of the antigen-binding site. Earlier studies by Scheck and Francis [32] have also reported that epitope recognition and antigen-binding capabilities of antibody and fab fragments remain unaffected after selective modification of their N-terminus amines.
Our studies with antibody fragments prepared from mAbK1 showed a K d value equal to 22.7 ± 6.4 nM and 25.0 ± 1.3 nM for 99m Tc-fab and 99m Tc-f(ab 0 ) 2 , respectively (Fig. 4) . To further evaluate whether labeling through N-terminal amines caused a loss of mesothelin affinity in antibody fragments, we carried out control studies to test the affinity of 99m Tc-labeled mAbK1 and 111 In-labeled mAbK1 (data not shown). For these studies, 99m Tc labeling of mAbK1 was accomplished by direct labeling through thiol groups using the 'pretinning' method [33] , whereas 111 In was labeled by lysine residues using 2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid. From these studies, we obtained K d values of 21.5 ± 2.8 nmol/l and 29.3 ± 2.3 nmol/l for 99m In-labeled mAbK1, respectively. These findings indicated that the radiolabeling through N-(ortho-phenol)-histidine chelator does not have any adverse impact on the affinity of the antibody.
Conclusion
A new bifunctional ligand was synthesized and evaluated for [ 99m Tc(CO) 3 ] + labeling of the fab and f(ab 0 ) 2 fragments of the antimesothelin antibody mAbK1. Our studies show that antibody fragments labeled using N-(ortho-phenol)-histidine chelator retain their antigenbinding ability and immunoreactivity, and have stabilities comparable with those of previously reported antibody fragments labeled through genetically expressed histidine tags. From our findings, it is evident that [ 99m Tc(CO) 3 ] + conjugation through the N-(ortho-phenol)-histidine chelator is a promising strategy for 99m Tc labeling of biomolecules such as antibodies, antibody fragments, peptides, and enzymes. Moreover, N-(ortho-phenol)-histidine chelator can also be potentially used for the [ 99m Tc(CO) 3 ] + labeling of amine-group-bearing polymers, which would facilitate the development of 99m Tc radiopharmaceuticals based on polymeric systems such as nanoparticles and microspheres. Representative total binding curves for (a) 99m Tc-fab and (b) 99m Tcf(ab 0 ) 2 . 
